Keywords: acp-103, cuts, pnss, score, ph, ii, trial
ACP-103 cuts PNSS score in Ph II trial
Article | 26 March 2007
The USA's Acadia Pharmaceuticals reported positive top-line results from a Phase II schizophrenia co-therapy trial with ACP-103, its proprietary and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
